Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with Enterobacterales Bacteremia

The Clinical and Laboratory Standards Institute (CLSI) revised the fluoroquinolone MIC breakpoints for Enterobacterales in 2019, based on pharmacokinetic/pharmacodynamic analyses. However, clinical evidence supporting these breakpoint revisions is limited. A retrospective study was conducted at 3 ho...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Huang, Ho-Yin, Wang, Chu-Feng, Lu, Po-Liang, Tseng, Sung-Pin, Wang, Ya-Ling, Chen, Tun-Chieh, Chang, Ko, Tu, Hung-Pin, Lin, Shang-Yi
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2021
Soggetti:
Clinical Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8315969/
https://ncbi.nlm.nih.gov/pubmed/33782006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00074-21
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi